FR11C0027I1 - RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENETIC TREATMENT - Google Patents
RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENETIC TREATMENTInfo
- Publication number
- FR11C0027I1 FR11C0027I1 FR11C0027C FR11C0027I1 FR 11C0027 I1 FR11C0027 I1 FR 11C0027I1 FR 11C0027 C FR11C0027 C FR 11C0027C FR 11C0027 I1 FR11C0027 I1 FR 11C0027I1
- Authority
- FR
- France
- Prior art keywords
- vaccines
- influenza viruses
- recombinant influenza
- genetic treatment
- genetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title abstract 2
- 230000002068 genetic effect Effects 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000712431 Influenza A virus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention provides a composition useful to prepare influenza A viruses, e.g., in the absence of helper virus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12791299P | 1999-04-06 | 1999-04-06 | |
US13283999P | 1999-05-06 | 1999-05-06 | |
PCT/US2000/009021 WO2000060050A2 (en) | 1999-04-06 | 2000-04-05 | Recombinant influenza viruses for vaccines and gene therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
FR11C0027I1 true FR11C0027I1 (en) | 2011-08-26 |
FR11C0027I2 FR11C0027I2 (en) | 2021-12-31 |
Family
ID=26826080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR11C0027C Active FR11C0027I2 (en) | 1999-04-06 | 2011-07-26 | RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENETIC TREATMENT |
Country Status (19)
Country | Link |
---|---|
EP (4) | EP2910629B1 (en) |
JP (3) | JP5543048B2 (en) |
KR (1) | KR100702275B1 (en) |
CN (2) | CN1350578B (en) |
AT (2) | ATE368729T1 (en) |
AU (1) | AU4073300A (en) |
BR (1) | BRPI0009580B8 (en) |
CA (2) | CA2928263A1 (en) |
CY (2) | CY1108520T1 (en) |
DE (6) | DE60035778T2 (en) |
DK (3) | DK1820853T3 (en) |
ES (3) | ES2290024T3 (en) |
FR (1) | FR11C0027I2 (en) |
HK (2) | HK1148778A1 (en) |
IL (2) | IL145702A0 (en) |
MX (1) | MXPA01010082A (en) |
NL (2) | NL300364I2 (en) |
PT (2) | PT1820853E (en) |
WO (1) | WO2000060050A2 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
EP2910629B1 (en) * | 1999-04-06 | 2018-09-19 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
US8715940B2 (en) | 1999-04-06 | 2014-05-06 | Wisconsin Alumni Research Foundation | Method of making recombinant influenza virus |
GB9916794D0 (en) * | 1999-07-16 | 1999-09-22 | Isis Innovation | In vitro virus reconstitution |
DK1194580T4 (en) * | 1999-07-14 | 2011-01-03 | Sinai School Medicine | In-vitro reconstitution of segmented negative-stranded RNA viruses |
US6951754B2 (en) | 2000-04-28 | 2005-10-04 | St. Jude Children's Research Hospital | DNA transfection system for the generation of infectious influenza virus |
EP1862550A1 (en) * | 2000-06-23 | 2007-12-05 | Wyeth Holdings Corporation | Assembly of wild-type and chimeric influenza virus-like particles (VLPs) |
IL153290A0 (en) * | 2000-06-23 | 2003-07-06 | American Cyanamid Co | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
US7211378B2 (en) | 2002-01-31 | 2007-05-01 | Wisconsin Alumni Research Foundation | Filovirus vectors and noninfectious filovirus-based particles |
ES2563402T3 (en) | 2002-02-13 | 2016-03-15 | Wisconsin Alumni Research Foundation | Signal for influenza virus vector packaging |
US7465456B2 (en) | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
WO2003091401A2 (en) | 2002-04-26 | 2003-11-06 | Medimmune Vaccines, Inc. | Multi plasmid system for the production of influenza virus |
WO2004112831A2 (en) * | 2003-05-28 | 2004-12-29 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines and gene therapy |
WO2005018539A2 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
JP4771959B2 (en) | 2003-12-23 | 2011-09-14 | メディミューン,エルエルシー | Multiple plasmid systems for influenza virus production |
FR2866031B1 (en) * | 2004-02-11 | 2012-10-19 | David Francois Joseph Millet | EMERGING PATHOGENIC VIRUS CHIMER, MEDICAMENT CONTAINING THE SAME, AND USE IN ANTIVIRAL THERAPY |
WO2005107797A1 (en) | 2004-03-09 | 2005-11-17 | Chiron Corporation | Influenza virus vaccines |
EP1771552B1 (en) | 2004-05-25 | 2012-08-01 | MedImmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
AU2005337178A1 (en) | 2004-11-19 | 2007-04-19 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with tandem transcription units |
CN101128598B (en) | 2004-12-08 | 2013-04-24 | 米迪缪尼有限公司 | Methods of producing influenza vaccine compositions |
JP5620048B2 (en) | 2004-12-24 | 2014-11-05 | アボツト・バイオロジカルズ・ベー・ブイAbbott Biologicals B.V. | Influenza virus rescue |
WO2006098901A2 (en) | 2005-03-08 | 2006-09-21 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
JP2009514838A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant vaccine containing non-virion antigen prepared from influenza virus grown in cell culture |
DE202006021242U1 (en) | 2005-11-04 | 2014-01-29 | Novartis Vaccines And Diagnostics S.R.L. | Free aqueous phase surfactant emulsions as an adjuvant for split flu vaccines |
CN102755645A (en) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | Influenza vaccines with reduced amount of emulsion adjuvant |
ES2377884T3 (en) | 2005-11-04 | 2012-04-02 | Novartis Vaccines And Diagnostics S.R.L. | Flu vaccines that include combinations of particulate adjuvants and immunopotentiators |
PT2529747T (en) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof |
DK2478916T3 (en) | 2006-01-27 | 2020-06-15 | Seqirus Uk Ltd | Influenza vaccines containing hemagglutinin and matrix proteins |
CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
WO2007126810A2 (en) | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
WO2007146057A2 (en) * | 2006-06-09 | 2007-12-21 | Wisconsin Alumni Research Foundation | Screening method for modulators of viral transcription or replication |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2049662A4 (en) | 2006-07-21 | 2009-12-30 | Medimmune Llc | Methods and compositions for increasing replication capacity of an influenza virus |
KR101586968B1 (en) | 2006-08-09 | 2016-01-20 | 메디뮨 엘엘씨 | Influenza hemagglutinin and neuraminidase variants |
ES2694805T7 (en) | 2006-09-11 | 2021-10-21 | Seqirus Uk Ltd | Manufacture of flu virus vaccines without using eggs |
SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
WO2008147496A2 (en) | 2007-05-04 | 2008-12-04 | Warf - Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
US8673613B2 (en) | 2007-06-18 | 2014-03-18 | Medimmune, Llc | Influenza B viruses having alterations in the hemaglutinin polypeptide |
EP2185191B1 (en) | 2007-06-27 | 2012-09-12 | Novartis AG | Low-additive influenza vaccines |
EP2045323A1 (en) * | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
CN101497877B (en) * | 2008-01-28 | 2012-09-05 | 河北摩百生物科技有限公司 | Influenza all-virus attenuated live vaccine recombinant, construction method and use thereof |
CN101998990B (en) | 2008-03-18 | 2013-11-27 | 诺华股份有限公司 | Improvements in preparation of influenza virus vaccine antigens |
CN102149405A (en) | 2008-07-11 | 2011-08-10 | 米迪缪尼股份有限公司 | Influenza hemagglutinin and neuraminidase variants |
WO2010021289A1 (en) | 2008-08-18 | 2010-02-25 | 学校法人北里研究所 | Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration |
EP2233568A1 (en) | 2009-03-19 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade AG | Novel method for generation of RNA virus |
EA201171032A1 (en) | 2009-02-10 | 2012-02-28 | Новартис Аг | TREATMENT SCHEMES WITH THE HELP OF VACCINE AGAINST FLU, ASSOCIATED WITH PANDEMIC STRAINS |
US20120093860A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
JP5642712B2 (en) | 2009-02-10 | 2014-12-17 | ノバルティス アーゲー | Influenza vaccine with low amounts of squalene |
MX2011008497A (en) | 2009-02-12 | 2011-12-16 | Us Gov Nat Inst Health | Influenza hemagglutinin and neuraminidase variants. |
USH2284H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
KR20120081587A (en) | 2009-09-10 | 2012-07-19 | 노파르티스 아게 | Combination vaccines against respiratory tract diseases |
US9109013B2 (en) | 2009-10-26 | 2015-08-18 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
CN103237890A (en) | 2010-06-02 | 2013-08-07 | 巴克斯特保健股份有限公司 | Novel method for generation of RNA virus |
CN102220293B (en) * | 2011-05-26 | 2012-12-19 | 中国农业科学院上海兽医研究所 | Dog flu recombinant virus as well as preparation method and application thereof |
ES2655051T3 (en) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Influenza virus with mutant PB2 gene segment as live attenuated vaccines |
EP2751260A2 (en) | 2011-09-02 | 2014-07-09 | Westfälische Wilhelms-Universität Münster | Live attenuated influenza virus |
WO2013057715A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
AU2014290203B2 (en) | 2013-07-15 | 2020-12-24 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
CN104450695B (en) * | 2014-11-26 | 2017-08-25 | 扬州大学 | Influenza A gene PCR amplimer and its rapid clon method |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
EP3307308A2 (en) * | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
KR20180035807A (en) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | Antigenically matched influenza vaccine |
WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
BR112018000296A2 (en) | 2015-07-07 | 2018-09-04 | Seqirus UK Limited | influenza potency tests |
WO2017040203A1 (en) * | 2015-08-28 | 2017-03-09 | Yoshihiro Kawaoka | Generation of infectious influenza viruses from virus-like particles |
AU2017221444B2 (en) | 2016-02-19 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza B virus replication for vaccine development |
US11013695B2 (en) * | 2017-08-28 | 2021-05-25 | Wisconsin Alumni Research Foundation | Nanocapsule delivery system for ribonucleoproteins |
CN107964035B (en) * | 2017-12-06 | 2020-07-24 | 中国科学院微生物研究所 | Limited replication type mucosal immune vaccine for influenza virus |
CN109097341B (en) * | 2018-08-28 | 2021-09-24 | 青岛农业大学 | Replication-defective recombinant influenza virus capable of simultaneously expressing HA and HEF |
JP2022527235A (en) | 2019-01-23 | 2022-06-01 | 義裕 河岡 | Mutations that impart genetic stability to additional genes in influenza virus |
CN113874496A (en) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | Humanized cell lines |
US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840520A (en) * | 1989-08-28 | 1998-11-24 | Aviron | Recombinant negative strand RNA virus expression systems |
US5658772A (en) | 1989-12-22 | 1997-08-19 | E. I. Du Pont De Nemours And Company | Site-specific recombination of DNA in plant cells |
US5919676A (en) * | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
AU3760495A (en) * | 1994-09-30 | 1996-04-26 | Aviron | Chimeric Influenza Virus And Electroporation Method |
EP0704533A1 (en) * | 1994-09-30 | 1996-04-03 | Bayer Ag | An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus |
CN1200675A (en) * | 1995-10-20 | 1998-12-02 | 耶路撒冷希伯来语大学依苏姆研究开发公司 | Influenza vaccine |
US5994526A (en) * | 1996-06-21 | 1999-11-30 | Plant Genetic Systems | Gene expression in plants |
EP1035209A1 (en) * | 1999-03-06 | 2000-09-13 | ARTEMIS Pharmaceuticals GmbH | Stable recombinant influenza viruses free of helper viruses |
EP2910629B1 (en) * | 1999-04-06 | 2018-09-19 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
-
2000
- 2000-04-05 EP EP14200291.4A patent/EP2910629B1/en not_active Expired - Lifetime
- 2000-04-05 KR KR1020017012743A patent/KR100702275B1/en active IP Right Grant
- 2000-04-05 CA CA2928263A patent/CA2928263A1/en not_active Abandoned
- 2000-04-05 BR BRPI0009580A patent/BRPI0009580B8/en not_active IP Right Cessation
- 2000-04-05 DK DK07009953.6T patent/DK1820853T3/en active
- 2000-04-05 CA CA2365526A patent/CA2365526C/en not_active Expired - Lifetime
- 2000-04-05 AU AU40733/00A patent/AU4073300A/en not_active Abandoned
- 2000-04-05 DE DE60035778T patent/DE60035778T2/en not_active Expired - Lifetime
- 2000-04-05 AT AT00920151T patent/ATE368729T1/en active
- 2000-04-05 DK DK10011896.7T patent/DK2345716T3/en active
- 2000-04-05 MX MXPA01010082A patent/MXPA01010082A/en active IP Right Grant
- 2000-04-05 DE DE122008000035C patent/DE122008000035I1/en active Pending
- 2000-04-05 PT PT07009953T patent/PT1820853E/en unknown
- 2000-04-05 ES ES00920151T patent/ES2290024T3/en not_active Expired - Lifetime
- 2000-04-05 EP EP10011896.7A patent/EP2345716B1/en not_active Expired - Lifetime
- 2000-04-05 WO PCT/US2000/009021 patent/WO2000060050A2/en active IP Right Grant
- 2000-04-05 ES ES07009953T patent/ES2373405T3/en not_active Expired - Lifetime
- 2000-04-05 DE DE122008000058C patent/DE122008000058I1/en active Pending
- 2000-04-05 PT PT00920151T patent/PT1185615E/en unknown
- 2000-04-05 EP EP07009953A patent/EP1820853B1/en not_active Expired - Lifetime
- 2000-04-05 DK DK00920151T patent/DK1185615T3/en active
- 2000-04-05 CN CN00807495XA patent/CN1350578B/en not_active Expired - Lifetime
- 2000-04-05 DE DE122008000061C patent/DE122008000061I1/en active Pending
- 2000-04-05 EP EP00920151A patent/EP1185615B1/en not_active Expired - Lifetime
- 2000-04-05 ES ES10011896.7T patent/ES2533622T3/en not_active Expired - Lifetime
- 2000-04-05 CN CN201010155623.8A patent/CN101851636B/en not_active Expired - Lifetime
- 2000-04-05 AT AT07009953T patent/ATE525461T1/en active
- 2000-04-05 DE DE200812000014 patent/DE122008000014I1/en active Pending
- 2000-04-05 IL IL14570200A patent/IL145702A0/en unknown
- 2000-04-05 JP JP2000609542A patent/JP5543048B2/en not_active Expired - Lifetime
-
2001
- 2001-09-30 IL IL145702A patent/IL145702A/en not_active IP Right Cessation
-
2007
- 2007-10-08 CY CY20071101295T patent/CY1108520T1/en unknown
-
2008
- 2008-11-13 NL NL300364C patent/NL300364I2/en unknown
- 2008-11-13 NL NL300365C patent/NL300365I2/en unknown
-
2011
- 2011-03-22 HK HK11102898.6A patent/HK1148778A1/en not_active IP Right Cessation
- 2011-04-21 JP JP2011095240A patent/JP5775351B2/en not_active Expired - Lifetime
- 2011-07-26 FR FR11C0027C patent/FR11C0027I2/en active Active
- 2011-07-26 DE DE201112100037 patent/DE122011100037I1/en active Pending
- 2011-12-12 CY CY20111101234T patent/CY1112140T1/en unknown
-
2015
- 2015-03-31 JP JP2015071406A patent/JP6224645B2/en not_active Expired - Lifetime
-
2016
- 2016-02-25 HK HK16102164.8A patent/HK1214298A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR11C0027I2 (en) | RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENETIC TREATMENT | |
DK1021547T3 (en) | Vaccine formulations containing papilloma virus capsomes and methods for their use | |
EA200201279A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL HEPATITIS C | |
BRPI0309631A8 (en) | tetravalent dengue vaccine containing a trivial deletion of 30 nucleotides in the utr-31 'of dengue types 1,2,3 and 4, or chimeric dengue antigenic viruses 1,2,3 and 4 | |
UA85536C2 (en) | Viral antigens | |
MX342639B (en) | High titer recombinant influenza viruses for vaccines and gene therapy. | |
BG102712A (en) | Mixture of recombinant vaccinia vectors as polyenv-vaccines against hiv | |
ATE295180T1 (en) | PREPARATION FOR IMMUNIZATION AGAINST THE AIDS VIRUS | |
ATE395078T1 (en) | VACCINE FOR PREVENTION OR TREATMENT OF HEPATITIS C | |
BR0310020A (en) | Expression of genes in modified vaccinia virus ankara by use of vaccinia ati promoter | |
DE60024259D1 (en) | SEPARATION OF A HUMAN RETROVIRUS | |
DK1339737T3 (en) | Immunomodulatory protein formed from Yaba monkey tumor virus | |
FI964784A (en) | Virus recombinants, preparation and use in gene therapy | |
NZ511168A (en) | Recombinant CELO virus and CELO virus DNA | |
DE60035680D1 (en) | COMPLETE GENESQUENCE OF THE ELEKTROUS ANEMIEVIRUS DONKEY LEUKOCYTE VACCINE TREATMENT AND ITS APPLICATION | |
ATE189604T1 (en) | EXTRACTS OF PILIOSTIGMA THONNINGII, THEIR USE AND PREPARATIONS CONTAINING THEM | |
WO2002039116A3 (en) | Retrovirus isolated from humans | |
WO2000018430A3 (en) | Live virus vaccines to protect primates from hiv-1 infection and disease | |
WO2000024876A3 (en) | Spumavirus isolated from humans |